ArticleJournal of blood medicine2026
Malignancy-Associated Hemophagocytic Lymphohistiocytosis: An Experience of 15 Years in Polish Pediatric Hematology Centers.
Article in Journal of blood medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: M-HLH is a type of HLH that most often occurs in children in the course of hematological malignancies. The diagnosis is based on meeting the criteria of the HLH-2004 Protocol. The disease has a rapid course, and the lack of proper diagnosis and treatment threatens the patient's life. Methods: The paper presents the thorough clinical characteristics, course of treatment, and treatment results in 23 patients treated in pediatric hemato-oncology centers in Poland and reported to Polish HLH registry. HLH diagnostic criteria, CNS involvement, coexisting viral infections, genetic test results, treatment modalities, therapeutic responses, relapse incidence, and final outcomes were analyzed. Clinical and laboratory factors were subjected to statistical analysis. Overall survival was estimated using the Kaplan-Meier method for the entire cohort and separately for subgroups defined by type of malignancy and treatment strategy. Separate univariable Cox proportional hazards models were used to explore the association between selected clinical factors and survival. Results: The median age at diagnosis was 11.7 years, in 8 patients HLH symptoms preceded the cancer diagnosis. Acute leukemia was the factor causing M-HLH in 12 patients, in the remaining patients it was lymphoma. The treatment included tumor-directed therapy with or without HLH-directed therapy. The probability of survival in the study group was 0.539 (95% CI 0.364-0.798). Remission of HLH was statistically significant (p-value = 0.0007) and reduced the risk of death by 90% (HR=0.10). Conclusion: Quick and precise diagnosis and implementation of appropriate treatment bringing the patient into HLH remission is extremely important for survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.